US · OPTH · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Optimi Health Corp. (OPTH) intrinsic value and stock valuation
$1.51as of 2026-11-21 · Mkt cap 16.26M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Optimi Health Corp. DCF and intrinsic value
InvestorsCraft values OPTH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OPTH’s statements →
Optimi Health Corp. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2020–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Golden Agri-Resources Ltd (GARPY) $26.50
- Jones Soda Co. (JSDA) $0.30
- China Tontine Wines Group Limited (CATWF) $0.07
- Clean Seas Seafood Limited (CTUNF) $0.08
- Kun Peng International Ltd (KPEA) $0.37
- Big Rock Brewery Inc. (BRBMF) $0.59
- Burcon NutraScience Corporation (BRCNF) $1.05
- Cellev8 Nutrition Inc. (CELV) $0.08
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $430K | $390K | $180K | $80K | $0.00 |
| Operating income | -$-4.53M | -$-5.61M | -$-4.38M | -$-6.63M | -$-5.3M |
| Net income | -$-3.72M | -$-6.04M | -$-5.19M | -$-7.35M | -$-6.02M |
| EPSd | -$-1.16M | -$-2.03M | -$-1.79M | -$-2.83M | -$-2.58M |
| Operating cash flow | -$-2.63M | -$-4.28M | -$-3.6M | -$-4.58M | -$-6.02M |
| Capital expenditure | -$-90K | -$-150K | -$-800K | -$-7.15M | -$-4.94M |
| Free cash flow | -$-2.72M | -$-4.43M | -$-4.41M | -$-11.73M | -$-10.96M |
| Total assets | $15.2M | $14.6M | $16.5M | $16.8M | $23.5M |
| Total debt | $6.69M | $2.75M | $1.71M | $160K | $250K |
| Net debt | $5.55M | $2.65M | $360K | -$-1.73M | -$-8.18M |
| Total equity | $6.58M | $9.58M | $13.2M | $16M | $21.1M |
| Cash and short-term investments | $1.15M | $100K | $1.34M | $1.89M | $12.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $430K | $390K | $180K | $80K | $0.00 |
| Cost of revenue | $2.5M | $120K | $340K | $30K | $50K |
| Gross profit | -$-2.08M | $270K | -$-160K | $50K | -$-50K |
| Research and development expenses | $350K | $140K | $150K | $130K | $240K |
| Selling, general and administrative expenses | $2.72M | $3.99M | $3.93M | $7.02M | $5.06M |
| Other expenses | -$-610K | $1.74M | $140K | $290K | $0.00 |
| Operating expenses | $2.46M | $5.88M | $4.22M | $7.44M | $5.3M |
| Cost and expenses | $4.96M | $6M | $4.56M | $6.72M | $5.3M |
| Interest income | $10K | $0.00 | $140K | $70K | $60K |
| Interest expense | $530K | $430K | $40K | $30K | $20K |
| Depreciation and amortization | $950K | $870K | $730K | $290K | $0.00 |
| Ebitda | -$-2.23M | -$-4.74M | -$-4.42M | -$-7.03M | -$-5.35M |
| Operating income | -$-4.53M | -$-5.61M | -$-4.38M | -$-6.63M | -$-5.3M |
| Total other income/expenses, net | $820K | -$-430K | -$-810K | -$-720K | -$-720K |
| Income before tax | -$-3.72M | -$-6.04M | -$-5.19M | -$-7.35M | -$-6.02M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-3.72M | -$-6.04M | -$-5.19M | -$-7.35M | -$-6.02M |
| Weighted average shares outstanding | $3.2M | $2.98M | $2.9M | $2.6M | $2.33M |
| Weighted average diluted shares outstanding | $3.2M | $2.98M | $2.9M | $2.6M | $2.33M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.15M | $100K | $1.34M | $1.89M | $12.4M |
| Net receivables | $100K | $120K | $170K | $100K | $190K |
| Inventory | $310K | $890K | $780K | $260K | $120K |
| Total current assets | $1.83M | $1.23M | $2.43M | $2.43M | $14.3M |
| Property, plant and equipment, net | $12.6M | $13.3M | $14.1M | $14.4M | $8.9M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $13.4M | $13.3M | $14.1M | $14.4M | $9.16M |
| Total assets | $15.2M | $14.6M | $16.5M | $16.8M | $23.5M |
| Accounts payable | $1.19M | $750K | $900K | $560K | $2.11M |
| Short-term debt | $6.4M | $990K | $40K | $90K | $100K |
| Deferred revenue | $210K | $120K | $110K | -$-560K | $0.00 |
| Total current liabilities | $8.5M | $3.22M | $1.61M | $730K | $2.24M |
| Long-term debt | $320K | $1.76M | $1.67M | $70K | $160K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $160K | $1.76M | $1.67M | $70K | $160K |
| Capital lease obligations | $180K | $30K | $70K | $160K | $250K |
| Total liabilities | $8.65M | $4.98M | $3.28M | $800K | $2.4M |
| Common stock | $31.7M | $31.2M | $28.7M | $26.6M | $25.2M |
| Retained earnings | -$-27.28M | -$-23.61M | -$-17.65M | -$-13.43M | -$-6.19M |
| Accumulated other comprehensive income (loss) | $2.12M | $2.03M | $2.16M | $2.83M | $2.1M |
| Total equity | $6.58M | $9.58M | $13.2M | $16M | $21.1M |
| Total investments | $10K | $0.00 | $0.00 | $0.00 | $4M |
| Total debt | $6.69M | $2.75M | $1.71M | $160K | $250K |
| Net debt | $5.55M | $2.65M | $360K | -$-1.73M | -$-8.18M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-3.71M | -$-6.04M | -$-5.19M | -$-7.35M | -$-6.02M |
| Depreciation and amortization | $950K | $870K | $730K | $290K | $50K |
| Stock-based compensation | $50K | $60K | $160K | $1.01M | $1.26M |
| Change in working capital | $1.25M | $760K | $830K | $1.33M | -$-1.49M |
| Accounts receivable | $30K | $40K | -$-70K | $90K | -$-100K |
| Inventory | $500K | $20K | -$-210K | -$-260K | $0.00 |
| Accounts payable | -$-50K | -$-130K | $990K | $0.00 | $260K |
| Net cash provided by operating activities | -$-2.63M | -$-4.28M | -$-3.6M | -$-4.58M | -$-6.02M |
| Investments in property, plant and equipment | -$-90K | -$-150K | -$-800K | -$-7.15M | -$-4.94M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-90K | -$-150K | -$-710K | -$-3.15M | -$-9.19M |
| Common stock issued | $400K | $2.04M | $1.84M | $1.3M | $18.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $3.76M | $3.19M | $3.76M | $1.19M | $19.2M |
| Net change in cash | $1.04M | -$-1.24M | -$-540K | -$-6.54M | $3.96M |
| Cash at end of period | $1.15M | $100K | $1.34M | $1.89M | $8.43M |
| Operating cash flow | -$-2.63M | -$-4.28M | -$-3.6M | -$-4.58M | -$-6.02M |
| Capital expenditure | -$-90K | -$-150K | -$-800K | -$-7.15M | -$-4.94M |
| Free cash flow | -$-2.72M | -$-4.43M | -$-4.41M | -$-11.73M | -$-10.96M |
Line items
Line items
Line items
About Optimi Health Corp.
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.
- CEO
- Dane Stevens
- Employees
- 6
- Beta
- 1.59
Explore
Frequently asked questions
What is the intrinsic value of Optimi Health Corp. (OPTH)?
InvestorsCraft does not currently publish an intrinsic value for OPTH. How the IC value is calculated.
Is OPTH undervalued?
InvestorsCraft does not publish an undervaluation signal for OPTH at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.